• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4790050)   Today's Articles (6020)
For:  [Subscribe] [Scholar Register]
Number Cited by Other Article(s)
1
Buti M, Calleja JL, Rodríguez MÁ, Domínguez-Hernández R, Cantero H, Espinoza-Cámac N, Casado MÁ. Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D. GASTROENTEROLOGIA Y HEPATOLOGIA 2025;48:502241. [PMID: 39251019 DOI: 10.1016/j.gastrohep.2024.502241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2024] [Revised: 08/12/2024] [Accepted: 09/02/2024] [Indexed: 09/11/2024]
2
Forns X, Rodríguez M, Domínguez-Hernández R, Cantero H, Salinas-Ortega L, Casado MÁ. Cost analysis of hidden hepatitis D virus infection in Spain. GASTROENTEROLOGIA Y HEPATOLOGIA 2025:502337. [PMID: 39793729 DOI: 10.1016/j.gastrohep.2025.502337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Revised: 12/10/2024] [Accepted: 12/20/2024] [Indexed: 01/13/2025]
3
Jindal A, Sarin SK. TREAT-B or Treat All: time for a broader vision on hepatitis B elimination. Lancet Glob Health 2024;12:e916. [PMID: 38762293 DOI: 10.1016/s2214-109x(24)00174-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Accepted: 04/11/2024] [Indexed: 05/20/2024]
4
Luong Nguyen LB, Lemoine M, Ndow G, Nayagam S, Shimakawa Y. TREAT-B or Treat All: time for a broader vision on hepatitis B elimination - Author's reply. Lancet Glob Health 2024;12:e917. [PMID: 38762294 DOI: 10.1016/s2214-109x(24)00175-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Accepted: 04/11/2024] [Indexed: 05/20/2024]
5
Sinakos E, Kachru N, Tsoulas C, Jeyakumar S, Smith NJ, Yehoshua A, Cholongitas E. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece. J Comp Eff Res 2024;13:e230090. [PMID: 38317634 PMCID: PMC11044955 DOI: 10.57264/cer-2023-0090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Accepted: 01/18/2024] [Indexed: 02/07/2024]  Open
6
Buti M, Domínguez-Hernández R, Palom A, Esteban R, Casado MÁ. Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis. Liver Int 2023;43:2611-2614. [PMID: 37916574 DOI: 10.1111/liv.15776] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 08/02/2023] [Accepted: 10/23/2023] [Indexed: 11/03/2023]
7
Congly SE, Syed A, Haylock-Jacobs S, Israelson H, Pinto J, Williams S, Lee SS, Coffin CS. A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B. CANADIAN LIVER JOURNAL 2023;6:305-313. [PMID: 38020196 PMCID: PMC10652987 DOI: 10.3138/canlivj-2022-0043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 11/20/2022] [Indexed: 12/01/2023]
8
Koffas A, Mak LY, Gill US, Kennedy PTF. Early Treatment Consideration in Patients with Hepatitis B 'e' Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? Viruses 2022;14:v14050900. [PMID: 35632642 PMCID: PMC9143099 DOI: 10.3390/v14050900] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 04/22/2022] [Accepted: 04/22/2022] [Indexed: 02/04/2023]  Open
9
Premkumar M, Chawla YK. Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia. J Clin Exp Hepatol 2022;12:144-154. [PMID: 35068795 PMCID: PMC8766700 DOI: 10.1016/j.jceh.2021.08.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2021] [Accepted: 08/22/2021] [Indexed: 01/03/2023]  Open
10
Wigfield P, Sbarigia U, Hashim M, Vincken T, Heeg B. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. PHARMACOECONOMICS - OPEN 2020;4:403-418. [PMID: 31428938 PMCID: PMC7426349 DOI: 10.1007/s41669-019-00175-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA